Gannet BioChem Appoints Dr. Harry Rathore As New Board Member To Strengthen Leadership

Gannet BioChem, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in specialty chemicals, has announced the appointment of Harry Rathore to its Board of Directors. This development comes shortly after the company’s recent acquisition by Ampersand Capital Partners, a private equity firm with a focus on growth equity investments in the life sciences and healthcare industries.

Harry Rathore brings over 35 years of experience in leadership roles across the specialty chemicals, pharmaceutical, and CDMO sectors. His extensive background includes serving as President and Chief Executive Officer of Callery Inc., as well as holding senior executive positions at companies such as Lonza AG, Alcami, and Borregaard Synthesis. In addition to his executive roles, he is the founder of PolyOrganix, Inc., a company focused on specialty pharmaceuticals and fine chemicals.

Nick Shackley, CEO, Gannet Biochem, said in a statement, “With a strong background building and advising businesses in the specialty chemical and pharmaceutical industries, Harry will provide valuable insight and guidance to enable Gannet BioChem’s growth and innovation. I look forward to working closely with Harry as we execute our strategic growth plan in support of therapeutics globally.”

Mr. Rathore, Gannet BioChem’s Board of Directors, stated, “I’m honored to join the Board of Directors at Gannet BioChem during such a pivotal time in the company’s growth. With a proven track record spanning 30 years, Gannet’s specialized capabilities in PEG reagents, bioconjugation and GMP manufacturing are essential to advancing the next generation of biopharmaceuticals.”

Currently, Mr. Rathore serves on the boards of Ascensus Specialties and VanDeMark, Inc., where he also acts as a strategic advisor, contributing his expertise to guide business growth and development. His academic background includes a Ph.D. in Medicinal Chemistry from Oregon State University, as well as a Master of Science and a Bachelor of Science in Pharmaceutical Sciences from Banaras Hindu University. His appointment to the board is expected to bring valuable insight and strategic direction to Gannet BioChem as the company continues to expand its capabilities and offerings under the ownership of Ampersand Capital Partners.